Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
Open Access
- 11 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (11), 3303-3313
- https://doi.org/10.1093/rheumatology/keaa084
Abstract
To evaluate upadacitinib efficacy and safety dose response in Japanese patients with active RA and an inadequate response to conventional synthetic DMARDs (csDMARDs). This was a multicentre, phase IIb/III, dose-ranging study conducted in Japan, in which patients on previously stable csDMARDs were randomized to receive upadacitinib 7.5, 15 or 30 mg once daily or matching placebo for a 12-week double-blind period. The primary endpoint was a 20% improvement in ACR criteria (ACR20) response at week 12 using non-responder imputation. Key secondary endpoints included ACR50, ACR70 and 28-joint DAS with CRP (DAS28-CRP) remission and low disease activity. Adverse events were also assessed. Of 197 patients treated, 187 completed the double-blind period. At week 12, more patients receiving upadacitinib 7.5, 15 or 30 mg vs placebo met the ACR20 response (75.5%, 83.7%, 80.0% vs 42.9%; P < 0.001), with significant differences observed as early as week 1. Stringent responses, including ACR50, ACR70 and DAS28-CRP vs upadacitinib 7.5 mg. Adverse events and infections (serious infections, opportunistic infections and herpes zoster) were more common with upadacitinib vs placebo and numerically highest with upadacitinib 30 mg. There were no venous thromboembolic events reported. Efficacy of upadacitinib was demonstrated in this population of Japanese patients with RA and an inadequate response to csDMARDs. Safety and tolerability were consistent with other upadacitinib RA studies. The 15 mg dose of upadacitinib showed the most favourable benefit–risk profile. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02720523.Keywords
Funding Information
- Masuyuki Yokoyama
- AbbVie
- AbbVie
- AbbVie
This publication has 28 references indexed in Scilit:
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis & Rheumatology, 2015
- The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysisSeminars in Arthritis and Rheumatism, 2014
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2014
- Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trialAnnals Of The Rheumatic Diseases, 2014
- Fatigue and Factors Related to Fatigue in Rheumatoid Arthritis: A Systematic ReviewArthritis Care & Research, 2013
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialThe Lancet, 2013
- The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatmentRheumatology, 2012
- The Pathogenesis of Rheumatoid ArthritisThe New England Journal of Medicine, 2011
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnnals Of The Rheumatic Diseases, 2010
- Psychosocial factors, disease status, and quality of life in patients with rheumatoid arthritisJournal of Psychosomatic Research, 2009